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ABSTRACT
Objective: To estimate the prevalence of prodromal clinical features of neurodegeneration in
patients with Anderson-Fabry disease (AFD) in comparison to age-matched controls.
Methods: This is a single-center, prospective, cross-sectional study in 167 participants
(60 heterozygous females and 50 hemizygous males with genetically confirmed AFD, 57 age-
matched controls) using a clinical screening program consisting of structured interview, quantita-
tive tests of motor function, and assessments of cognition, depression, olfaction, orthostatic
intolerance, pain, REM sleep behavior disorder, and daytime sleepiness.
Results: In comparison to age-matched controls (mean age 48.3 years), patients with AFD (mean
age 49.0 years) showed slower gait and transfer speed, poorer fine manual dexterity, and lower
hand speed, which was independent of focal symptoms due to cerebrovascular disease. Patients
with AFD were more severely affected by depression, pain, and daytime sleepiness and had a lower
quality of life. Thesemotor and nonmotormanifestations significantly correlatedwith clinical disease
severity. However, patients with AFD did not reveal extrapyramidal motor features or signs of sig-
nificant cognitive impairment, hyposmia, orthostatic intolerance, or REM sleep behavior disorder,
which commonly precede later neurodegenerative disease. In our cohort, there were no differences
in neurologic manifestations of AFD between heterozygous females and hemizygous males.
Conclusions: Aside from cerebrovascular manifestations and small fiber neuropathy, AFD results
in a distinct neurologic phenotype comprising poorer motor performance and specific nonmotor
features. In contrast to functional loss of glucocerebrosidase in Gaucher disease, a-galactosidase
deficiency in AFD is not associated with a typical cluster of clinical features prodromal for
neurodegenerative diseases, such as Parkinson disease. Neurology® 2015;84:1–11
GLOSSARY
a-Gal 5 a-galactosidase A; AFD 5 Anderson-Fabry disease; ALP 5 autophagy-lysosomal pathway; BDI 5 Beck Depression
Inventory; BPI5 Brief Pain Inventory; ERT5 enzyme replacement therapy; ESS5 Epworth Sleepiness Scale; GD5 Gaucher
disease; MDS-UPDRS 5 Movement Disorders Society–revised version of the Unified Parkinson’s Disease Rating Scale;
MMSE 5 Mini-Mental State Examination; MoCA 5 Montreal Cognitive Assessment; MSSI 5 Mainz Severity Score Index;
NIHSS 5 NIH Stroke Scale; PD 5 Parkinson disease; RBD 5 REM sleep behavior disorder; RBDSQ 5 REM Sleep Behavior
Disorder Screening Questionnaire; SF-36 5 36-item Short-Form health survey; SS-16 5 Sniffin’ Sticks 16-item smell
identification test.
Anderson-Fabry disease (AFD) is a rare X-linked lysosomal storage disorder resulting in defi-
ciency of the lysosomal enzyme a-galactosidase A (a-Gal)1 and progressive accumulation of
undegraded glycosphingolipids in various tissues. Neurologic manifestations of AFD include
small fiber neuropathy associated with pain and reduced temperature sensation2 and premature
cerebrovascular events,3 which are attributed to complex vasculopathy secondary to progressive
glycosphingolipid accumulation in vessels and to cardiac involvement.
Neuropathologic studies have shown that glycosphingolipid storage in AFD is not restricted
to the vasculature but also present in neurons of brain regions known to be affected in
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neurodegenerative diseases, such as the dorsal
motor nucleus of the vagus, substantia
nigra, and neocortex.4,5 Moreover, disrup-
tion of the autophagy-lysosomal pathway
(ALP) and focused presence of phosphorylated
a-synuclein-containing lesions in the pons have
been recently demonstrated in a-Gal-deficient
mice.6 Although Gaucher disease (GD), another
lysosomal storage disorder, has been shown to
be associated with at least a fivefold risk for
Parkinson disease (PD),7 and case reports have
described L-dopa-responsive parkinsonism in pa-
tients with AFD,8,9 the prevalence of prodromes
of neurodegeneration has not been examined in
this rare disease.
We report the results of a prospective, cross-
sectional study investigating the clinical signifi-
cance of neuronal glycosphingolipid storage in
AFD by examining prodromal features of neu-
rodegeneration in a large cohort of patients and
age-matched controls. We hypothesized that
neuronal glycosphingolipid storage and ALP
disruption in AFD would result in clinical
manifestations similar to those seen in GD
patients and carriers.10
METHODS Standard protocol approvals, registrations,
and patient consents. This prospective, cross-sectional study
had ethical approval from the North West London Research
Ethics Committee (REC number 10/H0720/21). Written
informed consent was obtained from all participants.
Participants. A total of 110 patients with AFD (60 heterozy-
gous females, 50 hemizygous males) were recruited between April
2011 and February 2012 from the Lysosomal Storage Disorders
Unit at the Royal Free London Hospital. Diagnosis was confirmed
by molecular genetic analysis in all patients except one female
(genetic data available on request). Fifty-seven controls, matched
to patients for age and ethnicity, were identified from volunteers
and nonmedical staff at the hospital. Controls were required to
have a negative family history for lysosomal storage disorders and
had no clinical signs of AFD. Neither patients nor controls had
been diagnosed with neurodegenerative diseases in the past.
Procedures. Test procedures were performed identically in pa-
tients and controls. All participants were assessed by the same
movement disorders specialist (M.L.) and underwent a structured
interview and detailed clinical screening for motor and nonmotor
prodromes of neurodegenerative diseases as explained below. Dis-
ease severity in patients with AFD was rated with the Mainz
Severity Score Index (MSSI).11 The presence of white matter
abnormalities, lacuna, and territorial infarctions on latest cerebral
MRI scans was used to document cerebrovascular sequelae of
AFD. Renal involvement was assessed by serum creatinine, serum
urea, glomerular filtration rate estimated by 51Cr-EDTA clear-
ance, and presence of proteinuria. Cardiac manifestations were
assessed by the interventricular septal diameter measured by the
latest transthoracic echocardiography.
Evaluation of motor function. Three tests were performed for
quantitative assessment of motor function: (1) the Timed Up and
Go, which is a basic measure of gait and transfer speed12; (2) the
Purdue Pegboard, a test of fine manual dexterity, motor speed,
and finger-eye coordination13; and (3) a shortened, 30-second
version of the alternate tap test, used for the assessment of
motor speed in the hands with a moderate requirement of
coordination and accuracy.14 Extrapyramidal motor symptoms
were evaluated with the activities of daily living and motor
subscales of the Movement Disorders Society–revised version of
the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS
parts II and III).15 The NIH Stroke Scale (NIHSS), a graded
neurologic examination rating speech and language, cognition,
visual field deficits, motor and sensory impairments, and ataxia,
was used to identify potential focal neurologic deficits due to
cerebrovascular disease.16
Evaluation of nonmotor function and quality of life. Cog-
nitive function was assessed with the Mini-Mental State
Examination (MMSE)17 and the Montreal Cognitive Assessment
(MoCA).18 The MoCA has been shown to be more sensitive for
the detection of mild cognitive impairment or dementia in PD
than other scales, with optimal cut-off scores of ,26 indicating
mild cognitive impairment and ,21 dementia.19 Depressive
symptoms were evaluated with the Beck Depression Inventory
(BDI) II.20 Olfactory function was assessed with the 16-item smell
identification test from Sniffin’ Sticks (SS-16; Burghart Messtechnik,
Wedel, Germany). Individuals with anatomical upper airway
abnormalities, respiratory tract infections, or a history of traumatic
head injury were excluded from the analysis. Hyposmia was
diagnosed at SS-16 scores ,11, which in the UK population have
shown to provide a PD probability of $50%.21 Resting blood
pressure and heart rate were taken after participants had been
resting for 5 minutes in supine position and 2 minutes after
standing up to check for signs of orthostatic intolerance. Drops of
$20 mm Hg in systolic blood pressure were considered to be
clinically significant. Pain was quantified with the Brief Pain
Inventory (BPI), which measures intensity of pain and the
interference of pain with the participant’s life.22 Features of REM
sleep behavior disorder (RBD) were identified with the REM Sleep
Behavior Disorder Screening Questionnaire (RBDSQ), which was
considered positive at scores of $5.23 Daytime sleepiness was
screened for with the Epworth Sleepiness Scale (ESS), with ESS
values .10 points indicating significant sleepiness.24 Quality of life
was assessed with the EQ-5D-5L25 and the 36-item Short-Form
health survey (SF-36).26
Statistical analyses. Statistical analyses were performed with
SPSS software, version 21.0 (SPSS, Chicago, IL). Since we
expected sex differences due to X-linked inheritance in AFD, sta-
tistical comparisons were initially carried out separately for female
and male participants with the unpaired t test or Mann-WhitneyU
test (continuous variables) and the x2 or Fisher exact test (discrete
variables), as appropriate. For comparison of continuous variables
between all participants, we used a general linear model with disease
and sex as fixed factors and age as covariate, which was valid in all
outcome parameters. The Spearman correlation was used to assess
the association of clinical outcomes and theMSSI. Pairwise deletion
was used for missing data. Unless stated otherwise, values are
displayed as unadjusted means 6 SD. Two-sided p values ,0.05
were deemed statistically significant.
RESULTS Study participants. A total of 110 patients
with AFD (60 heterozygous females, 50 hemizygous
males) and 57 controls (29 female, 28 male) were
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included in our cross-sectional study. Mean age, age
range, and ethnic background were similar between
patients and controls (table 1). Patients with AFD
were less likely to have university education and to
be employed and more likely to be medically retired
than controls. Hyperlipidemia and hypertension had
been diagnosed more often in patients, whereas other
cardiovascular risk factors were similar between groups.
Cerebrovascular events were more often reported by
patients with AFD, of whom 13.6% reported TIAs or
strokes in the past. Antidepressants were more
frequently found in the concomitant medication of
patients with AFD, whereas other CNS medications
were not different.
Disease characteristics in patients with AFD. Female and
male patients with AFD examined in this study had
been diagnosed a mean of 9.6 and 11.8 years ago,
respectively (table e-1 on the Neurology® Web site
at Neurology.org). Male patients were less likely to
have a positive family history for AFD at the time of
diagnosis than their female counterparts, indicating
that diagnosis in male patients had been made more
frequently following prior organ involvement.
Clinical disease severity rated with the MSSI was
higher in male than in female patients. In keeping with
higher disease severity, male patients with AFD were
treated more often with enzyme replacement therapy
(ERT), which had been initiated in 88% of male
and 60% of female patients. The difference in total
MSSI scores between sexes was due to higher renal
and cardiac subscores in male participants, whereas
general and neurologic MSSI subscores as well as the
point distribution in individual components of the
neurologic subscore were not different. Accordingly,
male patients showed more pronounced renal and car-
diac involvement on laboratory markers of renal func-
tion and transthoracic echocardiography, respectively,
whereas cerebral MRI reports did not indicate signifi-
cant differences in cerebrovascular manifestations
between female and male patients.
Structured interview. All participants were interviewed
for motor and nonmotor symptoms frequently
observed in neurodegenerative diseases (table e-2).
In brief, patients with AFD did not report extrapy-
ramidal motor features more often than controls.
When asked for nonmotor symptoms, patients more
frequently noted orthostatic problems, urinary dys-
function, constipation, depression, neuropathic pain,
and impaired hearing, whereas hyposmia, visual dis-
turbances, and sleep problems were not reported dif-
ferently in patients and controls.
Motor function. Quantitative assessments of motor
function in patients with AFD demonstrated lower
gait and transfer speed on the Timed Up and Go test
and poorer fine manual dexterity and hand speed on
the Purdue Pegboard and the alternate tap test,
respectively (table 2 and figure 1). Interestingly, these
impairments were still evident when we used the
NIHSS as covariate instead of age in order to correct
for potential focal neurologic deficits due to cerebrovas-
cular disease (results not shown). Evaluation of extrapy-
ramidal motor function with the MDS-UPDRS parts II
and III revealed higher scores in patients with AFD
compared to controls, indicating more impairment in
motor experiences of daily living and extrapyramidal
motor function. Evaluation of extrapyramidal
symptoms demonstrated more asymmetric motor
slowing and a trend for more postural instability in
patients with AFD, whereas frequencies of tremor,
rigidity, and reduced arm swing during gait were
similar between groups (figure 2). Assessment for focal
neurologic deficits with the NIHSS demonstrated very
low scores in all groups, although mean NIHSS scores
were slightly higher in patients with AFD, as expected in
a disease with known potential cerebrovascular
manifestations.
Motor function worsened with increasing age,
which we used as covariate in our statistical model.
Female participants performed better on the Purdue
Pegboard test, whereas male participants performed
better on the alternate tap test; otherwise, there were
no significant differences between sexes. Importantly,
we did not observe a combined effect of disease and
sex on motor function, arguing for similar disease
effects in female and male patients with AFD.
Nonmotor function and quality of life. Evaluation with
MMSE and MoCA did not reveal significant cogni-
tive deficits in patients with AFD, although mean
MoCA scores were slightly lower than in controls (fig-
ure 1) due to reduced performance in abstraction and
delayed recall (table 3). Depressive symptoms on the
BDI were more frequent and severe in patients with
AFD, who had significant and severe depression in
26.8% and 8.2% of cases, respectively. Testing with
the SS-16 did not show differences in olfactory
function between patients and controls, which was
also illustrated by similarly low frequencies of
hyposmia in all groups. During orthostatic challenge,
patients with AFD did not show more evidence for
orthostatic hypotension than age-matched controls.
BPI assessments revealed higher severity and functional
interference of pain in patients with AFD than in age-
matched controls, which upon visual inspection of the
questionnaires was frequently due to a combination of
joint problems and neuropathic pain. Evaluation with
the ESS revealed significantly higher scores for daytime
sleepiness in patients, whereas screening with the
RBDSQ provided no evidence for a higher frequency
of RBD in AFD. Although most patients were treated
with ERT, both female and male patients with AFD had
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Table 1 Demographic data of patients with Anderson-Fabry disease and age-matched controls
Female controls Female patients Male controls Male patients All controls All patients p Valuesa
No. of participants 29 60 28 50 57 110
Age, y
Mean (SD) 47.5 (17.9) 47.8 (16.1) 49.1 (17.1) 50.5 (15.9) 48.3 (17.4) 49.0 (16.0)
Min–max 21.6–88.2 17.3–84.4 23.7–86.3 19.0–81.2 21.6–88.2 17.3–84.4
Ethnic groups, n (%)
White 26 (89.7) 59 (98.3) 27 (96.4) 50 (100.0) 53 (93.0) 109 (99.1)
Asian 2 (6.9) 1 (1.7) 1 (3.6) 0 (0.0) 3 (5.3) 1 (0.9)
Black 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mixed 1 (3.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.8) 0 (0.0)
School education, y, n (%)
>12 21 (72.4) 22 (36.7)b 23 (82.1) 24 (48.0)b 44 (77.2) 46 (41.8) ,0.05b
12 (A-Levels) 4 (13.8) 10 (16.7) 2 (7.1) 3 (6.0) 6 (10.5) 13 (11.8)
11 (GCSE) 3 (10.3) 15 (25.0) 0 (0.0) 13 (26.0)b 3 (5.3) 28 (25.5) ,0.05b
<11 1 (3.4) 13 (21.7)b 3 (10.7) 10 (20.0) 4 (7.0) 23 (20.9) ,0.05b
Profession, n (%)
Studying 5 (17.2) 4 (6.7) 1 (3.6) 2 (4.0) 6 (10.5) 6 (5.5)
Employed 20 (69.0) 35 (58.3) 22 (78.6) 29 (58.0) 42 (73.7) 64 (58.2) ,0.05b
Housewife 0 (0.0) 5 (8.3) NA NA 0 (0.0) 5 (4.5)
Pensioned 4 (13.8) 10 (16.7) 5 (17.9) 9 (18.0) 9 (15.8) 19 (17.3)
Medically retired 0 (0.0) 4 (6.7) 0 (0.0) 5 (10.0) 0 (0.0) 9 (8.2) ,0.05b
Unemployed 0 (0.0) 2 (3.3) 0 (0.0) 5 (10.0) 0 (0.0) 7 (6.4)
Cardiovascular risk factors
Adipositas, n (%) 4 (13.8) 12 (20.0) 5 (17.9) 9 (18.0) 9 (15.8) 21 (19.1)
Body mass index, kg/m2, mean (SD) 25.3 (4.2) 25.9 (4.7) 26.9 (4.1) 25.7 (5.1) 26.1 (4.2) 25.8 (4.9)
Diabetes mellitus type 2, n (%) 1 (3.4) 2 (3.3) 1 (3.6) 4 (8.0) 2 (3.5) 6 (5.5)
Hyperlipidemia, n (%) 3 (10.3) 22 (36.7)c 4 (14.3) 19 (38.0)c 7 (12.3) 41 (37.3) 0.001c
Hypertension, n (%) 3 (10.3) 17 (28.3) 4 (14.3) 16 (32.0) 7 (12.3) 33 (30.0) 0.011c
Smoking, n (%) 4 (13.8) 9 (15.0) 4 (14.3) 10 (20.0) 8 (14.0) 19 (17.3)
Pack-years in smokers, mean (SD) 18.9 (16.6) 12.6 (16.1) 10.5 (11.7) 16.4 (11.8) 14.7 (14.1) 14.6 (12.4)
Cerebrovascular events, n (%)
None 28 (96.6) 50 (83.3) 28 (100.0) 45 (90.0) 56 (98.2) 95 (86.4) 0.013c
TIA 0 (0.0) 5 (8.3) 0 (0.0) 2 (4.0) 0 (0.0) 7 (6.4)
Stroke 1 (3.4) 5 (8.3) 0 (0.0) 3 (6.0) 1 (1.8) 8 (7.3)
Concomitant CNS medications, n (%)
Antidepressants 0 (0.0) 9 (15.0)d 0 (0.0) 4 (8.0) 0 (0.0) 13 (11.8) 0.005d
Antiparkinsonian agents 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Dopamine antagonists 1 (3.4) 0 (0.0) 0 (0.0) 1 (2.0) 1 (1.8) 1 (0.9)
Neuroleptics 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.0) 0 (0.0) 2 (1.8)
Abbreviations: GCSE 5 General Certificate of Secondary Education; NA 5 not applicable.
Nonsignificant p values were omitted for clarity. Significant differences within female and male participants with p , 0.05 additionally indicated by
cPearson x2 test, dFisher exact test, or bZ test. Means are provided as unadjusted means.
ap Values for comparisons between patients with Anderson-Fabry disease and age-matched controls.
bx2 test for equality of 2 proportions (Z test).
c Pearson x2 test.
d Fisher exact test.
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Table 2 Motor function and focal neurologic symptoms in patients with Anderson-Fabry disease and age-matched controls
Female controls Female patients Male controls Male patients All controls All patients
F and p values after GLM analysis
Disease Other factors
No. of participants 29 60 28 50 57 110
Right-handedness, n (%) 24 (82.8) 48 (80.0) 26 (92.9) 44 (88.0) 50 (87.7) 92 (83.6)
Quantitative tests of motor function
Timed Up and Go, s, mean (SD) 7.2 (1.6) 8.7 (2.9)a 7.2 (1.1) 8.8 (6.1)a 7.2 (1.4) 8.8 (4.6) F 5 5.8, p 5 0.018 Age: F 5 8.4, p 5 0.004
Purdue Pegboard test, pegs/30 s, mean (SD)
Dominant hand 16.4 (2.6) 15.0 (2.3)a 15.3 (2.3) 14.1 (2.5)a 15.9 (2.5) 14.6 (2.4) F 5 13.2, p , 0.001 Age: F 5 57.1, p , 0.001; sex: F 5 5.4, p 5 0.021
Nondominant hand 15.0 (2.4) 14.0 (2.2) 14.6 (2.3) 13.7 (2.1) 14.8 (2.4) 13.9 (2.2) F 5 7.4, p 5 0.007 Age: F 5 65.1, p , 0.001
Alternate tap test, taps/30 s, mean (SD)
Dominant hand 114.9 (17.1) 105.2 (22.7) 123.6 (13.9) 113.2 (22.0)a 119.1 (16.1) 108.9 (22.6) F 5 9.2, p 5 0.003 Age: F 5 14.2, p ,0.001; sex: F 5 8.0, p 5 0.005
Nondominant hand 105.1 (17.1) 96.4 (17.8) 111.0 (16.1) 101.8 (16.9)a 108.0 (16.7) 98.9 (17.5) F 5 10.4, p 5 0.002 Age: F 5 15.1, p ,0.001; sex: F 5 5.4, p 5 0.021
Extrapyramidal function, mean (SD)
MDS-UPDRS part II (M-EDL) 0.9 (1.8) 2.8 (4.5) 0.9 (1.6) 2.4 (6.2) 0.9 (1.7) 2.6 (5.3) F 5 5.5, p 5 0.021 Age: F 5 5.6, p 5 0.019
MDS-UPDRS part III (motor examination) 3.3 (5.2) 5.6 (6.1) 4.2 (3.6) 6.0 (6.0) 3.7 (3.9) 5.8 (6.0) F 5 5.6, p 5 0.019 Age: F 5 33.0, p , 0.001
Focal neurologic deficits, mean (SD)
NIHSS score, mean (SD) 0 (0) 0.28 (0.85)a 0.04 (0.19) 0.20 (0.78) 0.02 (0.13) 0.25 (0.82) F 5 4.1, p 5 0.046
Neurologic deficit, NIHSS ‡1, n (%) 0 (0) 9 (15.0)b 1 (3.6) 5 (10.0) 1 (1.8) 14 (12.7) (0.019)
Abbreviations: GLM5 general linear model; M-EDL5motor experiences of daily living; MDS-UPDRS5Movement Disorder Society–sponsored new version of the Unified Parkinson’s Disease Rating Scale; NIHSS5
NIH Stroke Scale.
Statistical comparison between controls and patients was performed with a GLM using disease and sex as fixed factors and age as covariate. Additional statistical comparison within female and male participants
was performed with Fisher exact test or Mann-Whitney test, as appropriate: ap, 0.05 within same sex with Mann-Whitney U test; bp, 0.05 within same sex with Fisher exact test. Values in parentheses represent
group analysis of NIHSS ordinal data performed with x2 test instead of GLM. Means are provided as unadjusted means. Nonsignificant p values have been omitted for clarity.
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a markedly reduced quality of life, as documented by the
EQ-5D-VAS and the SF-36 total scores (table 3).
Similar to motor function, age also affected sev-
eral nonmotor outcomes in patients and controls
(table 3). Higher age was associated with cognitive
decline on the MMSE and MoCA, a reduction of
olfactory function on the SS-16, a lower drop of
blood pressure and reduced compensatory increase
of heart rate upon standing up, higher pain severity
and interference indices on the BPI, more daytime
sleepiness on the ESS, and a lower quality of life on
both EQ-5D-VAS and SF-36 (not shown). Sex
effects were only identified during olfactory testing,
where female participants performed significantly
better than male participants (table 3). In keeping
with our observations on motor function, we did not
identify any differences in nonmotor outcomes
between female and male patients with AFD, again
indicating that the disease similarly affected both
sexes.
Figure 1 Motor and nonmotor outcomes in patients with Anderson-Fabry disease (red circles) and age-matched controls (blue circles)
Black bars indicate unadjusted mean values. N 5 110 and n 5 57 for patients with Anderson-Fabry disease (AFD) and age-matched controls, respectively.
*p , 0.05, **p , 0.01, ***p , 0.001 in comparison to age-matched controls with a general linear model using disease and sex as fixed factors and age as
covariate. Only disease effects are shown. BDI 5 Beck Depression Inventory; BPI 5 Brief Pain Inventory; ESS 5 Epworth Sleepiness Scale; MCI 5 mild
cognitive impairment; MoCA 5 Montreal Cognitive Assessment; RBD 5 REM sleep behavior disorder; RBDSQ 5 REM Sleep Behavior Disorder Screening
Questionnaire; SS-16 5 16-item smell identification test from Sniffin’ Sticks.
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Correlation of study outcomes with disease severity. In
order to assess whether neurologic symptoms would
also correlate with disease severity in AFD, we per-
formed bivariate correlations of all outcome parame-
ters with the MMSI (table e-3). Significant and
moderate correlations were found for all motor scales,
depression (BDI-II), pain (BPI), and quality of life
(EuroQoL Visual Analogue Scale, SF-36 score).
DISCUSSION We report a prospective, cross-sectional
study on prodromal symptoms of neurodegeneration in
a large cohort of patients with AFD aiming to evaluate
the clinical relevance of neuronal glycosphingolipid
accumulation in this rare disease. We found that
AFD is associated with impaired motor function and
various nonmotor symptoms, but unlike GD does
not lead to a pattern of extrapyramidal symptoms,
significant cognitive problems, hyposmia, or RBD
commonly preceding neurodegenerative diseases, in
particular PD27 and dementia with Lewy bodies.28
Aside from cardinal neurologic manifestations,
such as stroke29 and small fiber neuropathy,2 previous
studies have described depression,30 pain,31 and day-
time sleepiness32 in 46%, 53%, and 68% of patients
with AFD, respectively. Our study was able to repro-
duce these findings, but prevalence of these nonmo-
tor symptoms was lower in our cohort, possibly due
to ongoing symptomatic treatment or ERT in the
majority of cases. Nevertheless, it is noteworthy that
4 out of 9 severely depressed patients did not receive
treatment with antidepressants, reemphasizing the
need for recognition of depressive symptoms in this
disease. AFD was not associated with cognitive
impairment or autonomic dysfunction, which is in
keeping with previous, smaller studies.33–35 Moreover,
we were able to show that AFD does not result in
hyposmia or RBD, which are prodromal for later neu-
rodegenerative disease.
In addition, our study suggests that AFD does not
lead to extrapyramidal symptoms or parkinsonian
motor features but instead is associated with motor
impairments during gait and transfer and poorer fine
manual dexterity and hand speed. These deficits in
motor function correlated to clinical disease severity
similar to depression and pain, which emphasizes that
motor impairments are an integral part of the disease.
The pathophysiologic reasons for poorer motor per-
formance in AFD cannot be answered by our clinical
study and remain to be elucidated. Although cerebro-
vascular manifestations of AFD may lead to motor
impairment, it must be noted that frequency and bur-
den of cerebrovascular symptoms in our AFD cohort
was very low and that disease effects on motor func-
tion were still evident when results were corrected
for the presence of focal neurologic deficits. None
of our patients complained about sensory loss,
which is in agreement with previous neurophysiologic
studies demonstrating that small fiber dysfunction
predominates in the disease2 and argues against
peripheral neuropathy as the main reason for
impaired motor function. Interestingly, former neu-
ropathologic studies have shown that glycosphingo-
lipid accumulation in AFD is not limited to the
vasculature but can be found in neurons of various
brain regions, in particular the brainstem.4,5 Recently,
a study has demonstrated ALP disruption and focused
presence of phosphorylated a-synuclein-containing
lesions in the pons of a-Gal-deficient mice, which
were colocalized with large axonal spheroids indicat-
ing axonal degeneration.6 We therefore speculate that
Figure 2 Extrapyramidal motor symptoms in patients with Anderson-Fabry
disease (red bars) and age-matched controls (blue bars)
N 5 110 and n 5 57 for patients with Anderson-Fabry disease (AFD) and age-matched
controls, respectively. Symptoms were assessed during clinical evaluation with the Move-
ment Disorders Society–revised version of the Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS). Postural instability was evaluated with the pull test. Motor asymmetry was
defined as right-minus-left difference score$2 on side-specific MDS-UPDRS items. *Fisher
exact test. **Pearson x2 test.
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Table 3 Nonmotor function and quality of life in patients with Anderson-Fabry disease and age-matched controls
Female
controls
Female
patients
Male
controls
Male
patients
All
controls All patients
F and p values after GLM analysis for
Disease Other factors
No. of participants 29 60 28 50 57 110
Autonomic function (orthostatic challenge)
BP change at 2 minutes, mm Hg, mean (SD) 25.6 (11.1) 24.4 (10.6) 23.9 (14.1) 0.4 (11.9) 24.8 (12.6) 22.2 (11.4) Age: F 5 5.0, p 5 0.026
HR change at 2 minutes (1/min), mean (SD) 9.2 (9.1) 11.1 (9.2) 8.6 (7.0) 10.0 (6.5) 8.9 (8.0) 10.6 (8.0) Age: F 5 26.8, p , 0.001
Significant BP drop (>20 mm Hg), n (%) 2 (6.9) 4 (7.4) 4 (14.3) 2 (4.3) 6 (10.5) 6 (6.0)
Cognition
MMSE
Total score (0–30), mean (SD) 28.7 (1.5) 28.3 (2.0) 29.0 (1.3) 28.5 (1.5) 28.8 (1.4) 28.4 (1.8) Age: F 5 17.1, p , 0.001
Dementia (<24 points), n (%) 0 (0) 2 (3.3) 0 (0) 0 (0) 0 (0) 2 (1.2)
MoCA
Visuospatial and executive, mean (SD) 4.5 (0.7) 4.2 (1.0) 4.6 (0.7) 4.3 (0.8) 4.5 (0.7) 4.3 (0.9) Age: F 5 17.3, p , 0.001
Naming, mean (SD) 3.0 (0.2) 3.0 (0.2) 3.0 (0) 3.0 (0.1) 3.0 (0.2) 3.0 (0.2)
Attention, mean (SD) 5.4 (0.7) 5.4 (0.9) 5.8 (0.6) 5.8 (0.5) 5.6 (0.7) 5.6 (0.8) Age: F 5 7.7, p 5 0.006; sex: F 5 10.0, p 5 0.002
Language, mean (SD) 2.4 (0.7) 2.1 (0.9) 2.4 (0.7) 2.3 (0.8) 2.4 (0.7) 2.2 (0.9)
Abstraction, mean (SD) 1.8 (0.4) 1.8 (0.4) 2.0 (0.0) 1.8 (0.4)a 1.9 (0.3) 1.8 (0.4) F 5 6.1, p 5 0.014
Delayed recall, mean (SD) 4.4 (1.0) 3.8 (1.5)b 4.2 (0.8) 3.8 (1.2) 4.3 (0.9) 3.8 (1.4) F 5 6.3, p 5 0.013 Age: F 5 25.3, p , 0.001
Orientation, mean (SD) 5.9 (0.3) 5.9 (0.3) 5.9 (0.3) 5.9 (0.3) 5.9 (0.3) 5.9 (0.3)
Total score (0–30), mean (SD) 27.6 (2.3) 26.6 (2.8) 28.0 (1.6) 27.3 (2.0) 27.8 (2.0) 26.9 (2.5) F 5 5.0, p 5 0.027 Age: F 5 26.1, p , 0.001
MCI (<26 points), n (%) 4 (13.8) 15 (25.0) 2 (7.1) 8 (16.0) 6 (10.5) 23 (20.9) (p 5 0.093c)
Dementia (<21 points), n (%) 1 (3.4) 3 (5.0) 0 (0) 0 (0) 1 (1.8) 3 (2.7)
Depression
BDI-II
Total score, mean (SD) 3.8 (4.7) 11.3 (11.1)a 3.2 (3.5) 8.0 (8.6)a 3.5 (4.1) 9.8 (10.2) F 5 18.7, p , 0.001
Depression (>13 points), n (%) 2 (6.9) 19 (31.7)c 0 (0) 10 (20.0)d 2 (3.5) 29 (26.8) (p , 0.001c)
Severe depression (‡30 points), n (%) 0 (0) 5 (8.3) 0 (0) 4 (8.2) 0 (0) 9 (8.2) (p 5 0.028c)
Olfaction
SS-16
Total score (0–16), mean (SD) 13.5 (1.5) 13.5 (1.7) 12.7 (2.1) 12.9 (1.5) 13.1 (1.8) 13.2 (1.6) Age: F 5 4.5, p 5 0.035; sex: F 5 5.6, p 5 0.02
Hyposmia (<11 points), n (%) 1 (3.4) 3 (5.3) 2 (7.4) 2 (4.2) 3 (5.4) 5 (4.8)
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Table 3 Continued
Female
controls
Female
patients
Male
controls
Male
patients
All
controls All patients
F and p values after GLM analysis for
Disease Other factors
Pain
BPI
Pain severity index (0–10), mean (SD) 0.9 (1.6) 2.2 (2.4)b 0.7 (1.4) 1.5 (2.2)a 0.8 (1.5) 1.9 (2.3) F 5 9.8, p 5 0.002 Age: F 5 9.6, p 5 0.002
Function interference index (0–10), mean (SD) 0.6 (1.2) 1.9 (2.5)b 0.6 (1.4) 1.5 (2.6)a 0.6 (1.3) 1.7 (2.5) F 5 9.1, p 5 0.003 Age: F 5 4.8, p 5 0.03
Sleep
RBDSQ
Total score, mean (SD) 2.5 (2.0) 3.2 (2.8) 2.6 (1.9) 2.8 (2.7) 2.5 (1.9) 3.0 (2.8) Age: F 5 6.7, p 5 0.01
RBD (‡5 points), n (%) 5 (17.2) 16 (26.7) 3 (10.7) 13 (26.5) 8 (14.0) 29 (26.6)
ESS
Total score (0–24), mean (SD) 5.6 (3.9) 7.4 (5.1) 4.7 (4.4) 7.1 (4.8)b 5.1 (4.2) 7.2 (5.0) F 5 7.0, p 5 0.009 Age: F 5 5.7, p 5 0.018
Significant sleepiness (‡10 points), n (%) 5 (17.2) 16 (26.7) 6 (21.4) 12 (24.5) 11 (19.3) 28 (25.7)
Quality of life
EuroQol Visual Analogue Scale (0–100), mean (SD) 85.6 (19.8) 76.8 (19.0)a 83.9 (11.6) 72.6 (20.1)b 84.8 (16.1) 74.9 (19.5) F 5 10.9, p 5 0.001 Age: F 5 8.9, p 5 0.003
SF-36 total score (0–100), mean (SD) 84.6 (12.5) 62.8 (24.4)a 86.3 (12.0) 68.2 (23.9)a 85.4 (12.2) 65.2 (24.2) F 5 34.4, p , 0.001 Age: F 5 11.3, p 5 0.001
Abbreviations: BDI 5 Beck Depression Inventory; BP 5 blood pressure; BPI 5 Brief Pain Inventory; ESS 5 Epworth Sleepiness Scale; GLM 5 general linear model; HR 5 heart rate; MCI 5 mild cognitive impairment;
MMSE 5 Mini-Mental State Examination; MoCA 5 Montreal Cognitive Assessment; RBD 5 REM sleep behavior disorder; RBDSQ 5 REM Sleep Behavior Disorder Screening Questionnaire; SF-36 5 Short Form
Health Survey; SS-16 5 Sniffin’ Sticks 16-item smell identification test.
Statistical comparison between controls and patients was performed with a GLM using disease and sex as fixed factors and age as covariate. Additional statistical comparison within female and male participants
was performed with the x2 test, Fisher exact test, or Mann-Whitney U test: ap , 0.01, bp , 0.05, within same sex with Mann-Whitney U test. cp , 0.05 within same sex with x2 test. dp , 0.05 within same sex with
Fisher exact test. Values in parentheses represent p values derived from group analysis of MCI and depression rates performed with x2 test instead of GLM. Means are provided as unadjusted means. Nonsignificant
p values have been omitted for clarity.
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neuronal glycosphingolipid storage and ALP disrup-
tion in AFD lead to focused brainstem pathology,
which results in a distinct clinical phenotype with
mild motor impairment and nonmotor symptoms
such as depression, pain, daytime sleepiness, and
hearing loss, but is not associated with cardinal clin-
ical prodromes of neurodegenerative diseases, such as
parkinsonian motor signs and impairments of cogni-
tion and olfaction that are found in GD.10 However,
we would not completely rule out a contribution of
a-Gal deficiency to the development of neurodegen-
erative disease based on the lack of clinical prodromes,
especially as neuropathologic brainstem involvement
has also been demonstrated in presymptomatic stages
of PD.36
Another interesting observation of our study is the
similarity of neurologic manifestations in female and
male patients with AFD, which is in keeping with
other studies showing significant organ involvement
in female heterozygotes despite X-chromosomal
inheritance.37 Skewed inactivation of the X-chromo-
some was suspected to explain disease manifestations in
female patients, which is supported by recent research
demonstrating correlations between X-inactivation and
clinical disease severity in female patients.38 Molecular
interference by the mutant enzyme protein exerting
a dominant negative effect on the normal gene pro-
duct has also been suggested,39 but this explanatory
theory remains to be proven. While the reasons for
sex parity of disease manifestations in AFD remain to
be elucidated, our study should raise physicians’
awareness for symptoms in female patients with
AFD, who are often considered as carriers of but
not patients with the disease.
Strengths of our study in this rare disease include
its size, range, and complexity of clinical testing, and
the use of age-matched controls to enhance external
validity of the results. Due to its observational and
cross-sectional design, our study has some limitations,
which may have influenced its outcome. First, the
majority of patients in our AFD cohort were treated
with ERT, which may have partly altered the natural
phenotype of the disease and explain lower severity of
peripheral nonmotor symptoms, such as pain. How-
ever, ERT is unlikely to influence neurologic symp-
toms caused by central manifestations of AFD, such
as motor features, hyposmia, or RBD, since it cannot
cross the blood–brain barrier. Secondly, it must be
acknowledged that blinded examination was not possi-
ble due to facial stigmata and skin manifestations in
AFD, which may have subconsciously influenced our
assessments, although we applied well-established and
highly standardized clinical tests to minimize observer
bias. Third, sex comparison in our study may not
entirely reflect natural conditions in AFD carriers, since
our cohort was recruited from a university-based
specialty center, in which more severely affected female
patients may be overrepresented. Moreover, patients’
perception of having AFD may have contributed to
worse outcomes on questionnaires in comparison to
controls.
Taken together, our study argues for a distinct
neurologic phenotype in AFD that lacks classical pro-
dromal features of neurodegeneration that have been
demonstrated in GD. Unlike functional loss of gluco-
cerebrosidase in GD, which has been shown to be
involved in accumulation of a-synuclein and results
in neurotoxicity,40 AFD-linked deficiency of a-Gal is
apparently not associated with neurodegeneration on
the clinical level.
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